Models for prevention and treatment of cancer: problems vs promises.
暂无分享,去创建一个
B. Aggarwal | Bharat B Aggarwal | P. Gehlot | Divya Danda | Shan Gupta | Prashasnika Gehlot | D. Danda | Shan Gupta
[1] Jeffrey E. Green,et al. The use of genetically altered mice for breast cancer prevention studies. , 2003, The Journal of nutrition.
[2] Daniel,et al. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .
[3] Steven E Schild,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[4] R. Mayer,et al. Targeted therapy for advanced colorectal cancer--more is not always better. , 2009, The New England journal of medicine.
[5] C. Lindley,et al. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. , 2006, Clinical therapeutics.
[6] B. Kramer,et al. Trends in biomarker research for cancer detection. , 2001, The Lancet. Oncology.
[7] J. Isola,et al. Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance , 2007, Molecular Cancer Therapeutics.
[8] V. Baladandayuthapani,et al. Targeting cell signaling pathways for drug discovery: An old lock needs a new key , 2007, Journal of cellular biochemistry.
[9] J. Mendelsohn,et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. , 1984, Cancer research.
[10] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Prakash Chinnaiyan,et al. Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR) , 2004, Cancer Research.
[12] R. Kerbel,et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.
[13] A. Toland,et al. The role of parental and grandparental epigenetic alterations in familial cancer risk. , 2008, Cancer research.
[14] J. Ward,et al. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. , 1995, Cancer research.
[15] C. Heeschen,et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.
[16] S. Burchill. What do, can and should we learn from models to evaluate potential anticancer agents? , 2006, Future oncology.
[17] D. Cella,et al. Effects of Sorafenib on Symptoms and Quality of Life: Results From a Large Randomized Placebo-Controlled Study in Renal Cancer , 2007, American journal of clinical oncology.
[18] E. Lam,et al. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells , 2007, Molecular Cancer Therapeutics.
[19] Kaoru Kurisu,et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity , 2007, Molecular Cancer Therapeutics.
[20] S. Raghavan,et al. Chromosomal translocations in cancer. , 2008, Biochimica et biophysica acta.
[21] B. Aggarwal,et al. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. , 2009, Trends in pharmacological sciences.
[22] A. Polyzos. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors , 2008, The Journal of Steroid Biochemistry and Molecular Biology.
[23] M. Duvic,et al. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma , 2007, Expert opinion on investigational drugs.
[24] B. Giovanella,et al. Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. , 1972, Journal of the National Cancer Institute.
[25] C. Compton. Getting to personalized cancer medicine , 2007, Cancer.
[26] N. Hanna,et al. Second-Line Treatment of Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] K. Miller,et al. Redefining the target again: chemotherapeutics as vascular disrupting agents? , 2008, Cancer cell.
[28] S. Hilsenbeck,et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. , 2004, Journal of the National Cancer Institute.
[29] D. Scudiero,et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.
[30] R. Kerbel. Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved , 2003, Cancer biology & therapy.
[31] Lei Xu,et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.
[32] L. Ford,et al. Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[33] K. Flaherty. Sorafenib in Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[34] J. Alexander. Use of transgenic mice in identifying chemopreventive agents. , 2000, Toxicology letters.
[35] M. Campiglio,et al. Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. , 2004, Journal of the National Cancer Institute.
[36] L. Lesko,et al. Personalized Medicine: Elusive Dream or Imminent Reality? , 2007, Clinical pharmacology and therapeutics.
[37] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[38] A. Hasso,et al. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. , 2008, Surgical neurology.
[39] J. Cusack,et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.
[40] J. Lehár,et al. Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] B. Aggarwal,et al. Anticancer potential of silymarin: from bench to bed side. , 2006, Anticancer research.
[42] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.
[44] S. Ménard,et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. , 2007, Cancer research.
[45] P Smith,et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.
[46] Edwin Cuppen,et al. Zebrafish as a Cancer Model , 2008, Molecular Cancer Research.
[47] S. Ménard,et al. Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.
[48] L. Seymour,et al. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] F. Hirsch,et al. EGFR Inhibitors in the Treatment of Lung Cancer , 2007, Oncology Research and Treatment.
[50] I. Eltoum,et al. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. , 2007, Cancer research.
[51] B. Stockwell,et al. Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.
[52] D A Scudiero,et al. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. , 1997, Anti-cancer drug design.
[53] S. Cohen,et al. The stimulation of epidermal proliferation by a specific protein (EGF). , 1965, Developmental biology.
[54] R. Nahta,et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling (Molecular Cancer Therapeutics (2007) 6, (667-674)) , 2008 .
[55] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] G. Hortobagyi,et al. Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy , 2007, Cancer.
[57] S. Rafii,et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.
[58] P. Richardson,et al. Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2006, Annual review of medicine.
[59] M. Lacroix,et al. MDA-MB-435 cells are from melanoma, not from breast cancer , 2009, Cancer Chemotherapy and Pharmacology.
[60] M. Lipkin,et al. Preclinical Mouse Models for Cancer Chemoprevention Studies , 1999, Annals of the New York Academy of Sciences.
[61] R. Kucherlapati,et al. Mouse models for human familial adenomatous polyposis. , 2001, Seminars in cancer biology.
[62] R. Nahta,et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling , 2007, Molecular Cancer Therapeutics.
[63] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[64] W. Bodmer,et al. Common and rare variants in multifactorial susceptibility to common diseases , 2008, Nature Genetics.
[65] J. Isola,et al. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.
[66] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] A. Dachman,et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] M. Ychou,et al. Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting , 2008, Oncology.
[69] E. Hoal-van Helden,et al. Cross-contamination of human esophageal squamous carcinoma cell lines detected by DNA fingerprint analysis. , 1988, Cancer research.
[70] E. Raymond,et al. New developments in multitargeted therapy for patients with solid tumours. , 2008, Cancer treatment reviews.
[71] R. Orlowski,et al. The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.
[72] D. Goldenberg,et al. Malignant potential of murine stromal cells after transplantation of human tumors into nude mice. , 1981, Science.
[73] Subha Madhavan,et al. Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research , 2009, Molecular Cancer Research.
[74] A. Multani,et al. Can cancer cells transform normal host cells into malignant cells? , 1997, British Journal of Cancer.
[75] J. Verweij,et al. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? , 2006, European Journal of Cancer.
[76] F. Ciardiello,et al. Erlotinib in cancer treatment. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[77] D. Rall,et al. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man , 1970, Clinical pharmacology and therapeutics.
[78] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[79] A. Clarke,et al. The intestinal stem cell niche studied through conditional transgenesis. , 2006, Ernst Schering Foundation symposium proceedings.
[80] G. Mills,et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. , 2008, Cancer research.
[81] M. Hollingshead,et al. Antitumor efficacy testing in rodents. , 2008, Journal of the National Cancer Institute.
[82] Naoto T. Ueno,et al. P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.
[83] J. Venditti,et al. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. , 1984, Advances in pharmacology and chemotherapy.
[84] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[85] E. Hernando. Aneuploidy Advantages? , 2008, Science.
[86] P. Zarrinkar,et al. High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.
[87] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[88] N. Pavlidis,et al. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. , 2008, Critical reviews in oncology/hematology.
[89] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[90] M. Piccart,et al. Resistance to trastuzumab: a necessary evil or a temporary challenge? , 2002, Clinical breast cancer.
[91] R. Stafford,et al. Off-label prescribing among office-based physicians. , 2006, Archives of internal medicine.
[92] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[93] M. Clarke,et al. Cancer stem cells and tumor metastasis: first steps into uncharted territory. , 2007, Cell stem cell.
[94] Timothy W Gant,et al. Novel genomic methods for drug discovery and mechanism-based toxicological assessment. , 2009, Current opinion in drug discovery & development.
[95] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[96] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[97] J. Berlin,et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] W. Nelson-Rees,et al. Cross-contamination of cells in culture. , 1981, Science.
[99] J. Berlin,et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab , 2005, Journal of surgical oncology.
[100] H. Hurwitz,et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[101] B. Aggarwal,et al. Resveratrol: A multitargeted agent for age-associated chronic diseases , 2008, Cell cycle.
[102] D. Levêque. Off-label use of anticancer drugs. , 2008, The Lancet. Oncology.
[103] B. Aggarwal,et al. The guggul for chronic diseases: ancient medicine, modern targets. , 2008, Anticancer research.
[104] David J. Waxman,et al. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment , 2008, Molecular Cancer Therapeutics.
[105] J. Verweij,et al. Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'. , 2007, Annals of Oncology.
[106] Peter Greaves,et al. First dose of potential new medicines to humans: how animals help , 2004, Nature Reviews Drug Discovery.
[107] C. Schmidt. Urine biomarkers may someday detect even distant tumors. , 2009, Journal of the National Cancer Institute.
[108] A. Kung. Practices and pitfalls of mouse cancer models in drug discovery. , 2007, Advances in cancer research.
[109] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[110] J. Masters. HeLa cells 50 years on: the good, the bad and the ugly , 2002, Nature Reviews Cancer.
[111] O. Olopade,et al. Advances in Breast Cancer: Pathways to Personalized Medicine , 2008, Clinical Cancer Research.
[112] A. Maier,et al. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. , 2004, European journal of cancer.
[113] C F Arlett,et al. The use of dubious cell lines in research: is trust enough? , 2001, The Lancet. Oncology.
[114] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[115] Richard Simon,et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[116] A. Jubb,et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[118] S. Morrison,et al. Efficient tumor formation by single human melanoma cells , 2008, Nature.
[119] L. Kèlland,et al. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. , 2004, European journal of cancer.
[120] T. Yeatman,et al. On the eve of personalized medicine in oncology. , 2008, Cancer research.
[121] M. Noble,et al. Cancer stem cells. , 2006, The New England journal of medicine.
[122] B. Aggarwal,et al. From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. , 2007, Journal of the Society for Integrative Oncology.